In just over two years, Candriam’s Oncology Strategy has reached more than two billion US dollar in assets under management. Through this strategy, Candriam wants to contribute in the fight against cancer by financing continuing innovation through investments in companies working towards better diagnoses and treatment.
By investing in oncology companies, we build capital on the back of twenty years of experience in health care investing. Through this fund, we have a tangible impact with on the one hand a strategy that has been involved in the vast majority of novel oncology drug approvals and by donating up to 10% of the fund’s net management fees to cancer research organisations.
Couldn't attend our webinar but want answers? Find the replay and clarifications from Servaas Michielssens, Senior Biotechnology Analyst.